Vaccine options for influenza: thinking small

Schepens, Bert; Vlieger, Dorien De; Saelens, Xavier

doi:10.1016/j.coi.2018.03.024

Cited by 47 publications

(46 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mechanism of M2e-mediated protection is debated with both antibodies and T cells being important players (126)(127)(128). Several approaches have been undertaken to increase M2e immunogenicity, using VLP or different adjuvants (129)(130)(131). Of note, it appears that M2e antibodies act via effector functions and thus are infection permissive, making M2e vaccines more suitable when used in combination with others.…”

Section: M2e-based Vaccinesmentioning

confidence: 99%

Recombinant Influenza Vaccines: Saviors to Overcome Immunodominance

Mathew

Angeletti

2020

Front. Immunol.

View full text Add to dashboard Cite

It has been almost a decade since the 2009 influenza A virus pandemic hit the globe causing significant morbidity and mortality. Nonetheless, annual influenza vaccination, which elicits antibodies mainly against the head region of influenza hemagglutinin (HA), remains as the mainstay to combat and reduce symptoms of influenza infection. Influenza HA is highly antigenically variable, thus limiting vaccine efficacy. In addition, the variable HA head occupies the upper strata of the immunodominance hierarchy, thereby clouding the antibody response toward subdominant epitopes, which are usually conserved across different influenza strains. Isolation of monoclonal antibodies from individuals recognizing such epitopes has facilitated the development of recombinant vaccines that focus the adaptive immune response toward conserved, protective targets. Here, we review some significant leaps in recombinant vaccine development, which could possibly help to overcome B cell and antibody immunodominance and provide heterosubtypic immunity to influenza A virus.

show abstract

Section: M2e-based Vaccinesmentioning

confidence: 99%

Recombinant Influenza Vaccines: Saviors to Overcome Immunodominance

Mathew

Angeletti

2020

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Exploiting live attenuated Salmonella system to deliver IBV S1 immunogenic protein is a highly economical vaccination strategy that allows for a quick response to deployment of vaccines, as it circumvents the need for a constant supply of specific-pathogen-free (SPF) embryonated eggs. Furthermore, Salmonella -based vaccination strategy induces efficient antigen-specific humoral and cell-mediated immunity [ 17 – 19 ], and these vaccines have already been approved for use in poultry [ 20 ]. Herein, we show that attenuated SG mutant delivering immunogenic S1 protein elicited efficient IBV-specific humoral and cell-mediated immune (CMI) responses and conferred significant protection against a virulent IBV challenge.…”

Section: Introductionmentioning

confidence: 99%

Oral immunization with a novel attenuated Salmonella Gallinarum encoding infectious bronchitis virus spike protein induces protective immune responses against fowl typhoid and infectious bronchitis in chickens

Hajam

Kim

Lee

2018

Vet Res

View full text Add to dashboard Cite

Fowl typhoid (FT), a septicemic disease caused by Salmonella Gallinarum (SG), and infectious bronchitis (IB) are two economically important avian diseases that affect poultry industry worldwide. Herein, we exploited a live attenuated SG mutant, JOL967, to deliver spike (S) protein 1 of IB virus (V) to elicit protective immunity against both FT and IB in chickens. The codon optimized S1 nucleotide sequence was cloned in-frame into a prokaryotic constitutive expression vector, pJHL65. Subsequently, empty pJHL65 or recombinant pJHL65-S1 plasmid was electroporated into JOL967 and the resultant clones were designated as JOL2068 and JOL2077, respectively. Our results demonstrated that the chickens vaccinated once orally with JOL2077 elicited significantly (p < 0.05) higher IBV-specific humoral and cell-mediated immunity compared to JOL2068 and PBS control groups. Consequently, on challenge with the virulent IBV strain at 28th day post-vaccination, JOL2077 vaccinated birds displayed significantly (p < 0.05) lower inflammatory lesions in virus-targeted tissues compared to control groups. Furthermore, 33.3% (2 of 6) of birds vaccinated with JOL2077 vaccine had shown virus recovery from tracheal tissues compared to 100% (6 of 6) recovery obtained in both the control groups. Against wild-type SG lethal challenge, both JOL2077 and JOL2068 vaccinated groups exhibited only 10% mortality compared to 80% mortality observed in PBS control group. In conclusion, we show that JOL2077 can induce efficient IBV- and carrier-specific protective immunity and can act as a bivalent vaccine against FT and IB. Further studies are warranted to investigate the potential of JOL2077 vaccine in broiler and young layer birds.Electronic supplementary materialThe online version of this article (10.1186/s13567-018-0588-9) contains supplementary material, which is available to authorized users.

show abstract

“…In addition, developed models can be used in future investigations on other influenza virus amino acids compositions (such as M2E) and their possible roles in viral antigenicity. The findings clearly suggest the viral amino acid profiles of the influenza virus as potential features to monitor host specificity [34].…”

Section: Discussionmentioning

confidence: 99%

The First Implication of Image Processing Techniques on Influenza A Virus Sub-Typing Based on HA/NA Protein Sequences, using Convolutional Deep Neural Network

Ahsan¹,

Ebrahimi²

2018

Preprint

View full text Add to dashboard Cite

Increase in influenza A virus host range throughout its evolution has given rise to major concerns worldwide. Although the increasing host range mechanism of the virus is largely unknown; persistent genetic mutations have been blamed as a key factor in the re-organization of the host response and the host range. To uncover the underlying core bases of the two important antigenic proteins of influenza virus (HA and NA), functional data mining and image processing analysis of over 8000 protein sequences of different HA and NA subtypes were performed. Each amino acid sequence in HA or NA proteins sat as a feature or variable and two polynomial datasets were created and subjected into conventional prediction models.

show abstract

Vaccine options for influenza: thinking small

Cited by 47 publications

References 55 publications

Recombinant Influenza Vaccines: Saviors to Overcome Immunodominance

Recombinant Influenza Vaccines: Saviors to Overcome Immunodominance

Oral immunization with a novel attenuated Salmonella Gallinarum encoding infectious bronchitis virus spike protein induces protective immune responses against fowl typhoid and infectious bronchitis in chickens

The First Implication of Image Processing Techniques on Influenza A Virus Sub-Typing Based on HA/NA Protein Sequences, using Convolutional Deep Neural Network

Contact Info

Product

Resources

About